The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorPeking University

About this trial

The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are:

* Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years? * Is this combined approach more cost-effective than usual care alone? Researchers will compare the group receiving the digital mindfulness intervention plus their usual treatment to the group receiving only their usual treatment to see if the intervention leads to better long-term recovery and represents good value for money.

Participants in the intervention group will:

* Attend eight weekly 2-hour online group mindfulness sessions. * Use a WeChat mini-program for 49 days of guided mindfulness exercises and daily tasks. * Patients who have not achieved reliable recovery after group retraining voluntarily participate in individual UP\&MIED counseling. * Complete regular questionnaires and interviews over two years to track their progress.

All participants will continue to receive their usual medical care from their doctors throughout the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age: 18-65 years.

Diagnosed with an emotional disorder by a outpatient psychiatrist, including depressive disorders, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder), obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders (e.g., anorexia nervosa, bulimia nervosa).

Symptom severity meeting the threshold: PHQ-9 score ≥10 or GAD-7 score ≥8.

Disqualifiers

Current diagnosis of psychotic disorders or bipolar disorder.

Current organic mental disorders, pervasive developmental disorders, severe cognitive impairment, or substance use disorders.

Current suicide risk (PHQ-9 item 9 score >2).

Antisocial personality disorder.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Mindfulness Intervention for Emotional Distress

    Behavioral

    MIED is a psychological intervention program based on "Mindfulness-Based Stress Reduction" (MBSR) and the "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP), proposed by one of our authors. It includes a psychological diamond model of emotional distress and core intervention strategies (Liu, 2024). This program, in the form of mental health education courses, is suitable for patients with emotional disorders such as anxiety and depression. It has shown good effects in alleviating emotional distress in a series of preliminary studies (Ju et al., 2022; Li et al., 2023; Li et al., 2025; Wang et al., 2024). In this study, the intervention mainly adopts a step-care model, dynamically adjusting the intensity of the intervention according to the patient's recovery progress. All intervention content revolves around the four core transdiagnostic mechanisms of the MIED psychological diamond model and their corresponding core intervention strategies.

Treatment groups

464 Participants
are divided into 2 treatment groups
Group A: Intervention GroupExperimental treatment 1 intervention
Group B: TAU GroupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Time to Reliable Recovery

According to the standard definition of the IAPT (Improving Access to Psychological Therapies) system (El Baou et al., 2023; Gyani et al., 2013), reliable recovery requires meeting both of the following conditions simultaneously: (1) Reliable improvement: a decrease in PHQ-9 score of ≥6 points, or a decrease in GAD-7 score of ≥4 points, compared to baseline; (2) Symptoms below clinical thresholds: PHQ-9 \< 10 and GAD-7 \< 8. Time to reliable recovery is defined as the time from randomization to the first point at which both of the above criteria are met.

Time frame
at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention

Secondary outcomes

1

Time to relapse

Time to relapse is defined as the time from achieving reliable recovery to the point at which, at any follow-up assessment, either of the following criteria is met: a PHQ-9 score ≥ 10 or a GAD-7 score ≥ 8

Time frame
at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
2

Rate of reliable improvement

Reliable improvement is a decrease in PHQ-9 score of ≥6 points, or a decrease in GAD-7 score of ≥4 points, compared to baseline. The rate of reliable improvement was calculated at each assessment time point.

Time frame
at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
3

Rate of reliable recovery

Reliable recovery requires meeting both of the following conditions simultaneously: (1) Reliable improvement (2) Symptoms below clinical thresholds: PHQ-9 \< 10 and GAD-7 \< 8. The rate of reliable recovery was calculated at each assessment time point.

Time frame
at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
4

Deterioration rate

Deterioration is defined according to IAPT criteria as a clinically significant worsening from baseline, operationalized as: PHQ-9 increase ≥ 6 points, or GAD-7 increase ≥ 4 points. The rate of deterioration was calculated at each assessment time point.

Time frame
at baseline (T0), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention

Other outcomes

1

Changes of engaging in life

Measured using a self-developed scale assessing the extent to which individuals' daily engagement in life domains is affected by physical and psychological discomfort. The ELS-8, comprises 8 items across four domains (work/study, leisure, socializing, and sleep routine) rated on a five-point Likert scale (1 = not at all true, 5 = completely true). A total score of 8-40, with higher scores indicating that the individual is more engaged in life.

Time frame
at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
2

Changes of distress tolerance

The Distress Tolerance Scale is used to measure Distress Tolerance. Scores range from 5 to 75, with higher scores indicating higher levels of Distress Tolerance.

Time frame
at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
3

Changes of experiential avoidance

Experiential avoidance is measured with the Chinese version of the Brief Experiential Avoidance Questionnaire. 15 items are rated using a 6-point Likert scale ranging from 1 (strongly disagree) to 6 (strongly agree). Scores range from 15 to 90, with higher scores indicating higher levels of experiential avoidance.

Time frame
at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention
4

Changes of cognitive flexibility

The Cognitive Flexibility Inventory is a self-reported questionnaire measuring cognitive flexibility level. Scores range from 5 to 100, with higher scores indicating higher levels of cognitive flexibility.

Time frame
at baseline (T0), at week 3(T1) and at week 5 (T2), at post-intervention (T3), and at 6(T4), 12(T5), 18(T6), and 24(T7) months after the intervention

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University

Lead sponsor

WU'AN FIRST PEOPLE'S HOSPITAL

Collaborator

Xi'an Mental Health Center

Collaborator

The Second Hospital of Anhui Medical University

Collaborator

The Guangxi Zhuang Autonomous Region Brain Hospital

Collaborator

DONG GUAN SEVENTH PEOPLE'S HOSPITAL

Collaborator

Affiliated Mental Health Center of Kunming Medical University

Collaborator

People's Hospital of Zhengzhou University

Collaborator

The Affiliated Brain Hospital of Guangzhou Medical University

Collaborator

THE SIXTH AFFILIATED HOSPITAL OF GUANGDONG PHARMACEUTICAL UNIVERSITY

Collaborator

Xiamen Medical College Affiliated Xian Yue Hospital

Collaborator